$4.11
0.03[0.74%]
At close: Apr 26
$4.11
0[0.00%]
After Hours: 6:50PM EDT
Autolus Therapeutics
(NASDAQ:AUTL)Latest News for Autolus Therapeutics Stock (NASDAQ:AUTL)
Autolus Therapeutics Stock (NASDAQ: AUTL)
Categories: All
Friday, April 12, 2024
Thursday, April 11, 2024
Tuesday, April 09, 2024
Thursday, March 28, 2024
Wednesday, March 20, 2024
Monday, March 18, 2024
Friday, March 15, 2024
Thursday, March 14, 2024
- Needham Maintains Buy on Autolus Therapeutics, Maintains $9 Price TargetBenzinga Newsdesk - Mar 14, 2024, 3:28PM
- Autolus Therapeutics shares are trading higher after the company reported FY23 financial results.Benzinga Newsdesk - Mar 14, 2024, 11:31AM
- Autolus Therapeutics Reports Net Loss Per Share Of $(1.20) In FY23 Compared With $(1.57) YoY, Company Exits FY23 With Cash And Equivalents Worth $239,57MBenzinga Newsdesk - Mar 14, 2024, 7:07AM
- Earnings Scheduled For March 14, 2024Benzinga Insights - Mar 14, 2024, 5:52AM
Wednesday, March 13, 2024
Monday, February 12, 2024
- Autolus Therapeutics Option Alert: Mar 15 $7.5 Calls Sweep (5) near the Ask: 306 @ $0.85 vs 732 OI; Earnings 3/5 Before Open [est] Ref=$7.19Charles Gross - Feb 12, 2024, 10:20AM
- Autolus Therapeutics shares are trading higher after Needham maintained a Buy rating on the stock and raised its price target from $8 to $9.Benzinga Newsdesk - Feb 12, 2024, 10:12AM
- Needham Maintains Buy on Autolus Therapeutics, Raises Price Target to $9Benzinga Newsdesk - Feb 12, 2024, 6:34AM
Thursday, February 08, 2024
- Autolus Therapeutics Announced The Pricing Of An Underwritten Offering In The United States Of 58,333,336 American Depositary Shares (ADSs) Representing 58,333,336 Ordinary Shares At A $6.00 Per ADS, For Total Gross Proceeds Of $350MBenzinga Newsdesk - Feb 8, 2024, 7:05AM
- BioNTech, Autolus Announce Strategic CAR-T Cell Therapy Collaboration And BioNTech Will Pay $50M million, Additionally BioNTech Agrees To Invest $200M In AutolusBenzinga Newsdesk - Feb 8, 2024, 5:47AM
- BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage ProgramsBenzinga Newsdesk - Feb 8, 2024, 5:46AM
Monday, January 22, 2024
- Needham Maintains Buy on Autolus Therapeutics, Raises Price Target to $8Benzinga Newsdesk - Jan 22, 2024, 1:08PM
- CORRECTION: FDA Accepts Autolus Therapeutics' Marketing Application For Obecabtagene Autoleucel For Relapsed/Refractory Adult B-cell Acute Lymphoblastic Leukemia, With Target Action Date Of November 16, 2024Charles Gross - Jan 22, 2024, 7:16AM
- CORRECTION FDA Accepts Autolus Therapeutics' Marketing Application For Obecabtagene Autoleucel For Relapsed/Refractory Adult B-cell Acute Lymphoblastic Leukemia, With Target Action Date Of November 16, 2024Benzinga Newsdesk - Jan 22, 2024, 7:07AM
Wednesday, December 27, 2023
Wednesday, December 13, 2023
- Analyst Expectations for Autolus Therapeutics's FutureBenzinga Insights - Dec 13, 2023, 3:00PM
- Autolus Therapeutics shares are trading higher after Goldman Sachs maintained a Neutral rating on the stock and raised its price target from $3.2 to $4.8.Benzinga Newsdesk - Dec 13, 2023, 12:09PM
- Goldman Sachs Maintains Neutral on Autolus Therapeutics, Raises Price Target to $4.8Benzinga Newsdesk - Dec 13, 2023, 9:32AM
Sunday, December 10, 2023
Wednesday, November 29, 2023
Tuesday, November 28, 2023
Wednesday, November 15, 2023
Thursday, November 09, 2023
Thursday, November 02, 2023
- Autolus Therapeutics To Present Clinical Data Updates At The American Society Of Hematology Annual Meeting 2023 In Two Oral Presentations And Two Poster PresentationsBenzinga Newsdesk - Nov 2, 2023, 9:13AM
- Autolus Therapeutics Q3 EPS $(0.26) Misses $(0.25) Estimate, Sales $406.00K Miss $450.00K EstimateBenzinga Newsdesk - Nov 2, 2023, 7:15AM
- Earnings Scheduled For November 2, 2023Benzinga Insights - Nov 2, 2023, 4:56AM
Wednesday, October 25, 2023
Tuesday, September 05, 2023
Thursday, August 17, 2023
- Autolus Therapeutics' Obe-Cel's Shows Compelling Safety Over Gilead's Drug For Acute Lymphoblastic LeukemiaVandana Singh - Aug 17, 2023, 1:22PM
- Autolus Therapeutics shares are trading higher after Truist Securities maintained a Buy rating on the stock and raised its price target from $6 to $9.Benzinga Newsdesk - Aug 17, 2023, 12:02PM
- Truist Securities Maintains Buy on Autolus Therapeutics, Raises Price Target to $9Benzinga Newsdesk - Aug 17, 2023, 11:38AM
Thursday, August 03, 2023
Wednesday, July 19, 2023
Tuesday, June 27, 2023
Friday, June 16, 2023
Monday, June 05, 2023
Friday, June 02, 2023
- Where Autolus Therapeutics Stands With AnalystsBenzinga Insights - Jun 2, 2023, 2:01PM
- Autolus Therapeutics shares are trading higher after the company announced the presentation of top-line data from the Pivotal Phase 2 FELIX study of obe-cel in adult r/r B-cell Acute Lymphoblastic Leukemia at ASCO.Benzinga Newsdesk - Jun 2, 2023, 9:04AM